Evaluation of FROM-16 in ATMP Patients & Families

Summary

Poor health, and its treatment, has impact beyond the healthcare system into wider society. A person's productivity, taxable earnings, benefit payments and community contribution may all be adversely affected by poor health. Family members living with or caring for a patient may suffer equally, or sometimes more than the patient themselves, but this familial burden has gone largely unrecognised by healthcare systems. The Family-Reported Outcome Measure (FROM-16) is the first generic questionnaire designed to measure the impact of any chronic disease on the quality of life of family members or partners of patients with a health condition. Advance Therapy Medicinal Products (ATMPs) are a novel \& ground-breaking therapeutic approach for curative treatment of disease and/or injury where conventional treatments have been ineffective. Such disease/injury generally has an extremely high impact on the patient's quality of life, and also the quality of life of the patient's family, in particular those family members who take on the role of 'informal carer'. ATMPs usually have very high costs and this can limit their usage, especially in the context of low prevalence disease and publicly-funded healthcare systems, where healthcare providers may be reluctant to take on the cost burden of the ATMP therapy. As a result, there is a particular focus on the 'value' of ATMPs. An important component of value is 'Societal Value', where a treatment leads to societal contributions, and considering Societal Value may justify the high cost of ATMPs despite the relatively few patients cured. In this study, we will validate the FROM-16 for use as one measure of the Societal Value of very high cost, potentially curative treatments such as ATMPs.

Conditions

• Family Members
• Cancer

Interventions

OTHER

FROM-16 Questionnaire

A 16-item questionnaire to provide information about the impact of a patient's disease/condition the participants (family member of patient) quality of life

OTHER

Semi-structured two-part interview

A telephone/video interview to provide additional context to the FROM-16 responses

Sponsors & Collaborators

• Cardiff University

  collaborator OTHER

• University of Hertfordshire

  collaborator OTHER

• Cardiff and Vale University Health Board

  collaborator OTHER_GOV

• University Hospital Birmingham NHS Foundation Trust

  collaborator OTHER

• University Hospitals, Leicester

  collaborator OTHER

• University Hospitals Bristol and Weston NHS Foundation Trust

  collaborator OTHER

• Swansea University

  lead OTHER

Principal Investigators

• Hamish Laing · Swansea University

Eligibility

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2021-12-09

Primary Completion

2022-03-31

Completion

2022-03-31

Countries

• United Kingdom

Study Locations